Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"PsyBio Therapeutics","sponsor":"Advanced Biofuels","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I"},{"orgOrder":0,"company":"PsyBio Therapeutics","sponsor":"PsyBio Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PsyBio and Miami University Broaden Partnership for the Continued Advancement of its Neuropsychiatric Drug Discovery Platform","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"},{"orgOrder":0,"company":"PsyBio Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PsyBio Increases Intellectual Property Portfolio with Filing of Novel Genetic Optimization Pathways for Psychedelic Medication Biosynthesis","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by PsyBio Therapeutics

    Menu

    PsyBio Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              PsyBio Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PsyBio Increases Intellectual Property Portfolio with Filing of Novel Genetic Optimization Pathways for Psychedelic Medication Biosynthesis

              Details:

              PsyBio is tech transferring first two of its lead compounds, psilocybin and norbaeocystin, into process development and scaled manufacturing. This filing increases PsyBio's licensed patent portfolio to 4 pending provisional patents and 1 pending non-provisional patent.

              Lead Product(s): Psilocybine

              Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 12, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PsyBio Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PsyBio and Miami University Broaden Partnership for the Continued Advancement of its Neuropsychiatric Drug Discovery Platform

              Details:

              Under the Amended Agreement, the Jones Lab plans to develop elite microbes capable of efficient production of a range of medically-relevant alkaloids. The compounds of interest, Psilocybin, originate from a variety of plants and fungi, including magic mushrooms.

              Lead Product(s): Psilocybine

              Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Recipient: Miami University Broaden

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 26, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              PsyBio Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              PsyBio Therapeutics Initiates Process Development of Proprietary Biosynthetic Norbaeocystin

              Details:

              Norbaeocystin is an analogue of psilocybin and is not a controlled substance. The Company has commenced Phase I of this process, including analytical chemistry technical transfer to establish detection methods for fermentation products and key feedstocks and metabolites.

              Lead Product(s): Norbaeocystin

              Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Advanced Biofuels

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 23, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY